The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Resistance to enfuvirtide, the first HIV fusion inhibitor
Abstract
Fusion inhibitors are a new class of antiretroviral drugs (ARVs) for the treatment of human immunodeficiency virus infection. Enfuvirtide is the first in this class to reach market approval. Fusion inhibitors block the last step in the three-step viral entry process consisting of attachment, co-receptor binding and fusion, thereby preventing viral capsid entry into the host cell. Enfuvirtide has a unique mechanism of action and high viral target specificity, and in clinical trials has been shown to exhibit both high efficacy and low toxicity. Enfuvirtide is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation. Although different clinical isolates show variation in susceptibility to enfuvirtide, primary resistance has not been observed, and thus enfuvirtide-naive isolates remain clinically sensitive. Acquired resistance centres round a 10 amino acid motif between residues 36 and 45 in gp41 that forms part of the binding site of enfuvirtide. The 10 amino acid motif is critical for viral fusion, and enfuvirtide-resistant mutants show poor replicative capacity compared with wild type. Reversion to a wild-type, drug-sensitive state has been reported following enfuvirtide withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,172
Identification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,174
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,622
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Adverse effects of antiretroviral therapy
Carr, A., & Cooper, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02854-3 · Cited by 1,057
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,012
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., & Matthews, T. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9770 · Cited by 931
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
Functional Regions of the Envelope Glycoprotein of Human Immunodeficiency Virus Type 1
Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W. C., Terwilliger, E., Dayton, A., Rosen, C., Haseltine, W., & Sodroski, J. (1987) · Science · doi:10.1126/science.3629244 · Cited by 848
Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway
Brinkman, K., ter Hofstede, H. J. M., Burger, D. M., Smeitink, J. A. M., & Koopmans, P. P. (1998) · AIDS · doi:10.1097/00002030-199814000-00004 · Cited by 847
Lucas, G. M., Chaisson, R. E., & Moore, R. D. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-2-199907200-00002 · Cited by 843
Lasky, L. A., Nakamura, G., Smith, D. H., Fennie, C., Shimasaki, C., Patzer, E., Berman, P., Gregory, T., & Capon, D. J. (1987) · Cell · doi:10.1016/0092-8674(87)90524-1 · Cited by 828
Mitochondrial toxicity of antiviral drugs
Lewis, W., & Dalakas, M. C. (1995) · Nature Medicine · doi:10.1038/nm0595-417 · Cited by 770
Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., & Hunter, E. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8358-8367.2000 · Cited by 742
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
Lazzarin, A., Clotet, B., Cooper, D., Reynes, J., Arastéh, K., Nelson, M., Katlama, C., Stellbrink, H.-J., Delfraissy, J.-F., Lange, J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035211 · Cited by 656
Melikyan, G. B., Markosyan, R. M., Hemmati, H., Delmedico, M. K., Lambert, D. M., & Cohen, F. S. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.413 · Cited by 576
Monforte, A. D., Lepri, A. C., Rezza, G., Pezzotti, P., Antinori, A., Phillips, A. N., Angarano, G., Colangeli, V., Luca, A. D., Ippolito, G., et al. (2000) · AIDS · doi:10.1097/00002030-200003310-00005 · Cited by 554
Walli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D. (1998) · AIDS · doi:10.1097/00002030-199815000-00001 · Cited by 519
Capture of an early fusion-active conformation of HIV-1 gp41
Furuta, R. A., Wild, C. T., Weng, Y., & Weiss, C. D. (1998) · Nature Structural Biology · doi:10.1038/nsb0498-276 · Cited by 488
Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway, G. P., Katinger, H., Barbas, C. F., Burton, D. R., & Ho, D. D. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.6609-6617.1995 · Cited by 480
Wijnholds, J., Mol, C. A. A. M., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., Beijnen, J. H., Scheper, R. J., Hatse, S., De Clercq, E., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120159197 · Cited by 478
Eckert, D. M., Malashkevich, V. N., Hong, L. H., Carr, P. A., & Kim, P. S. (1999) · Cell · doi:10.1016/s0092-8674(00)80066-5 · Cited by 442
Dragic, T., Trkola, A., Thompson, D. A. D., Cormier, E. G., Kajumo, F. A., Maxwell, E., Lin, S. W., Ying, W., Smith, S. O., Sakmar, T. P., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090576697 · Cited by 426
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Reeves, J. D., Gallo, S. A., Ahmad, N., Miamidian, J. L., Harvey, P. E., Sharron, M., Pöhlmann, S., Sfakianos, J. N., Derdeyn, C. A., Blumenthal, R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252469399 · Cited by 404
A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion
Wild, C., Greenwell, T., & Matthews, T. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.1051 · Cited by 398
Structural basis for membrane fusion by enveloped viruses
Weissenhorn, Dessen, Calder, Harrison, Skehel, & Wiley, D. C. (1999) · Molecular Membrane Biology · doi:10.1080/096876899294706 · Cited by 372
A General Model for the Transmembrane Proteins of HIV and Other Retroviruses
GALLAHER, W. R., BALL, J. M., GARRY, R. F., GRIFFIN, M. C., & MONTELARO, R. C. (1989) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1989.5.431 · Cited by 368
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.
Earl, P. L., Doms, R. W., & Moss, B. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.2.648 · Cited by 359
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Robbins, G. K., De Gruttola, V., Shafer, R. W., Smeaton, L. M., Snyder, S. W., Pettinelli, C., Dubé, M. P., Fischl, M. A., Pollard, R. B., Delapenha, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030264 · Cited by 351
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Fellay, J., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., Hirschel, B., Vernazza, P., Francioli, P., Greub, G., Flepp, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06413-3 · Cited by 329
Strizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221375398 · Cited by 299
Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4
Peterson, A., & Seed, B. (1988) · Cell · doi:10.1016/0092-8674(88)90180-8 · Cited by 293
Drug Resistance Mutations in HIV-1.
D’Aquila, R. T., Schapiro, J., Brun‐Vézinet, F., Clotet, B., Conway, B., Demeter, L. M., Grant, R. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., et al. (2002) · PubMed · Cited by 276
Cell surface receptors, virus entry and tropism of primate lentiviruses
Clapham, P. R., & McKnight, Á. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-8-1809 · Cited by 256
Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
Kilby, J. M., & Eron, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022812 · Cited by 254
Shafer, R. W., Smeaton, L. M., Robbins, G. K., De Gruttola, V., Snyder, S. W., D'Aquila, R. T., Johnson, V. A., Morse, G. D., Nokta, M. A., Martinez, A. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030265 · Cited by 228
Trkola, A., Ketas, T. J., Nagashima, K. A., Zhao, L., Cilliers, T., Morris, L., Moore, J. P., Maddon, P. J., & Olson, W. C. (2001) · Journal of Virology · doi:10.1128/jvi.75.2.579-588.2001 · Cited by 224
Muñoz-Barroso, I., Salzwedel, K., Hunter, E., & Blumenthal, R. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.6089-6092.1999 · Cited by 224
Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
Shafer, R. W., Winters, M. A., Palmer, S., & Merigan, T. C. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-11-199806010-00008 · Cited by 197
Kuritzkes, D. R., Jacobson, J., Powderly, W. G., Godofsky, E., DeJesus, E., Haas, F., Reimann, K. A., Larson, J. L., Yarbough, P. O., Curt, V., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/380802 · Cited by 194
Toxicity of antiretroviral therapy and implications for drug development
Carr, A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1151 · Cited by 191
Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., & Hunter, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8605-8614.2001 · Cited by 182
Chen, C. H., Matthews, T. J., McDanal, C. B., Bolognesi, D. P., & Greenberg, M. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3771-3777.1995 · Cited by 169
Self-citationLalezari, J. P., Eron, J. J., Carlson, M., Cohen, C. J., DeJesus, E., Arduino, R. C., Gallant, J. E., Volberding, P. A., Murphy, R. L., Valentine, F. T., et al. (2003) · AIDS · doi:10.1097/00002030-200303280-00007 · Cited by 150
Lü, J., Sista, P. R., Giguel, F. F., Greenberg, M., & Kuritzkes, D. R. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4628-4637.2004 · Cited by 144
Self-citationMode of Action of an Antiviral Peptide from HIV-1
Kliger, Y., Gallo, S. A., Peisajovich, S. G., Muñoz‐Barroso, I., Avkin, S., Blumenthal, R., & Shai, Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m004113200 · Cited by 144
Weissenhorn, W., Wharton, S. A., Calder, L. J., Earl, P. L., Moss, B., Aliprandis, E., Skehel, J. J., & Wiley, D. C. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00494.x · Cited by 137
Insulin Resistance in HIV Protease Inhibitor–Associated Diabetes
Yarasheski, K. E., Tebas, P., Sigmund, C., Dagogo-Jack, S. E., Bohrer, A., TURK, J. W., Halban, P. A., Cryer, P. E., & Powderly, W. G. (1999) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-199907010-00005 · Cited by 128
Retroviral Envelope Glycoproteins Contain a "Leucine Zipper"-like Repeat
Delwart, E., Mosialos, G., & Gilmore, T. D. (1990) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1990.6.703 · Cited by 124
Williams, G. C., Liu, A., Knipp, G. T., & Sinko, P. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3456-3462.2002 · Cited by 122
Nagashima, K. A., Thompson, D. A. D., Rosenfield, S. I., Maddon, P. J., Dragic, T., & Olson, W. C. (2001) · The Journal of Infectious Diseases · doi:10.1086/319284 · Cited by 105
A General Model for the Surface Glycoproteins of HIV and Other Retroviruses
Gallaher, W. R., Ball, J. M., Garry, R. F., MARTIN-AMEDEE, A. M., & Montelaro, R. C. (1995) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1995.11.191 · Cited by 104
Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100
Tremblay, C. C. L., Kollmann, C. S., Giguel, F. F., Chou, T., & Hirsch, M. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200010010-00001 · Cited by 98
Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors
Labrosse, B., Labernardière, J., Dam, E., Trouplin, V., Skrabal, K., Clavel, F., & Mammano, F. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1610-1613.2003 · Cited by 92
Tremblay, C. L., Giguel, F. F., Kollmann, C. S., Guan, Y., Chou, T., Baroudy, B. M., & Hirsch, M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1336-1339.2002 · Cited by 86
Lalezari, J. P., DeJesus, E., Northfelt, D., Richmond, G. J., Wolfe, P., Haubrich, R., Henry, D. A., Powderly, W. G., Becker, S. L., Thompson, M., et al. (2003) · Antiviral Therapy · doi:10.1177/135965350300800403 · Cited by 79
Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor
Poveda, E., Rodés, B., Toro, C., Martín‐Carbonero, L., González‐Lahoz, J., & Soriano, V. (2002) · AIDS · doi:10.1097/00002030-200209270-00014 · Cited by 56
Roman, F. P., Gonzalez, D., Lambert, C., Deroo, S., Fischer, A., Baurith, T., Staub, T., Boulmé, R., Arendt, V., Schneider, F., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200306010-00003 · Cited by 53
de Rosny, E., Vassell, R. A., Wingfield, P. T., Wild, C. T., & Weiss, C. D. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8859-8863.2001 · Cited by 52
Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide
Boyd, M. A., Zhang, X., Dorr, A. E., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003259220 · Cited by 46
Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types
Ketas, T. J., Klasse, P. J., Spenlehauer, C., Nesin, M., Frank, I., Pope, M., Strizki, J., Reyes, G. R., Baroudy, B. M., & Moore, J. P. (2003) · AIDS Research and Human Retroviruses · doi:10.1089/088922203763315678 · Cited by 45
Hartt, J. K., Liang, T. S., Sahagún-Ruiz, A., Wang, J., Gao, J., & Murphy, P. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2846 · Cited by 37
Specific CD4 down-modulating compounds with potent anti-HIV activity
Vermeire, K., & Schols, D. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0403177 · Cited by 26
Cited by
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide
Münch, J., Ständker, L., Adermann, K., Schulz, A., Schindler, M., Chinnadurai, R., Pöhlmann, S., Chaipan, C., Biet, T., Peters, T., et al. (2007) · Cell · doi:10.1016/j.cell.2007.02.042 · Cited by 261
Metadata
- Authors
- Greenberg, M. L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 54
- Issue
- 2
- Pages
- 333-340
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2107672429
- Cited by
- 258
- References
- 71
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.